Immunology
Roughly 300 million people around the world suffer from immune-mediated diseases, including psoriatic disease, inflammatory bowel disease, and a wide variety of rare diseases. Of those, only a fraction receive advanced therapies that effectively treat their conditions.
Expand
Collapse
We have a bold vision: restore health for all patients with immune-mediated diseases. The fact that less than 10 percent of patients are considered in remission is simply unacceptable.
Focus areas
News
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5
TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis
TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis
NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)
The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases
The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+
Related stories
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
We are committed to partnering with those whose innovative thinking will bring new and creative solutions to the field of medicine
Our employees start each day with a new opportunity to transform healthcare and improve the quality of life for people in all corners of the world. We have made this our mission and our passion, and if you share this commitment, we are the right company for you.